This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the
combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC
with a KRAS G12C mutation.
Additional locations may be listed on ClinicalTrials.gov for NCT05840510.
See trial information on ClinicalTrials.gov for a list of participating sites.
This study will evaluate the safety and tolerability and clinical activity of adagrasib
in combination with nab-sirolimus in patients with advanced solid tumors harboring a KRAS
G12C mutation.
The Phase 1 portion will enroll advanced solid tumors to establish the maximum tolerated
dose (MTD) and/or to identify recommended Phase 2 combinatorial doses. The Phase 2
portion will enroll patients with NSCLC to further evaluate the safety/tolerability and
clinical activity.
Adagrasib is an orally available small molecule inhibitor of KRAS G12C. nab-Sirolimus is
a nanoparticle albumin-bound (nab) form of sirolimus, and sirolimus is an inhibitor of
mechanistic target of rapamycin kinase (mTOR, previously known as mammalian target of
rapamycin).
Lead OrganizationMirati Therapeutics
